I tried searching for this info. but could not find any article supporting this claim. yes there are discussions here and there, but not any concrete ones. I found an article where it was written generic drugs are way more cheaper than they should be. don’t know what it means exactly. but I don’t think they can increase prices because health system is already expensive in US. so only way companies can earn more profits is by doing backward integration and decreasing raw material prices.
Which quarter should show Teva unit revenue numbers contribution any idea ? Also anywhere we can check their USFDA observations response status ?
1 Like
Should reflect in Q1
3 Likes
it will reflect from q1 onwards.
iam very bullish for FY26 as company said they will double US revenue from 800CR to 1600CR. so even if UK revenue grows @15% for next 2 years and adding up TEVA’s revenue target of 1000CR for FY26 then company may acheive upwards of 4000CR for FY26.
6 Likes
HURRAY 
MARKSANS IS A BILLION $ COMPANY. RESILLEINCE OF PROMOTORS IS REALLY COMMENDABLE. FROM GOING TO NEAR BANKRUPTCY, THIS IS QUITE A JOURNEY.
WHAT DO YOU GUYS THINK IS THE NEXT MILESTONE FOR THIS CO.?
8 Likes